RLAY News and Press, Relay Therapeutics Inc. From 02/24/22

Announced RLY-4008 interim clinical data that suggest it is the first investigational therapy that selectively binds to FGFR2 and avoids off-isoform toxicities in the treatment of patients with FGFR2-altered tumors Shared preclinical data for RLY-2608, the first known allosteric...

CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report fourth quarter and full...

The following slide deck was published by Relay Therapeutics, Inc. in conjunction with this event. For further details see: Relay Therapeutics (RLAY) Investor Presentation - Slideshow

Doses first patient in first-in-human trial of RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor Selects 70 mg once-daily dose for RLY-4008 and initiates expansion cohorts in patients with FGFR2-altered solid tumors, including cholangiocarcinoma and bre...

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 9:45 a.m. ET. The presentation will be webcast live and may be accessed through Relay Ther...

Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have been added to Goldman Sach's Healthcare Strategic Asse...

CAMBRIDGE, Mass., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today shared additional preclinical dat...

Gainers: Pasithea Therapeutics (NASDAQ:KTTA) +257%, Petros Pharmaceuticals (NASDAQ:PTPI) +73%, Gracell Biotechnologies (NASDAQ:GRCL) +64%, iSpecimen (NASDAQ:ISPC) +43%, Qualigen Therapeutics (NASDAQ:QLGN) +33%. Losers: Longeveron (NASDAQ:LGVN) -36%...

Relay Therapeutics (NASDAQ:RLAY): Q3 GAAP EPS of -$0.66 misses by $0.01. Revenue of $0.66M beats by $0.51M. Press Release For further details see: Relay Therapeutics EPS misses by $0.01, beats on revenue

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported third quarter 2021 finan...